Abstract 9P
Background
To evaluate clinicopathological features and prognosis in women with mucinous breast cancer (MBC), distinguishing between pure (PMC) and mixed (MMC) subtype.
Methods
A retrospective analysis of all 358 women with MBC treated at Vietnam National Cancer hospital from June 2015 to December 2020. PMC was defined by ≥ 90% mucinous components.
Results
We identified 358 women with MBC (245 PMC and 113 MMC) representing 2.7% of all 13,254 breast cancer patients. The proportion of stage I, II, III and IV were 34.9%, 50.8%, 10.4% and 3.9% respectively. 95.3% of patients were hormone receptor positive. The rate of HER2 overexpression is 12%, and only 1.4% of patients was treated with anti-HER2. 193 patients (53.9%) had chemotherapy (CT), including 55 patients (15.4%) treated in neoadjuvant setting. Among those received neoadjuvant CT, only 3 patients (5.5%) achieved pCR. Meanwhile, the rates of partial response, stable disease and progressive disease were 50.8%, 38.2% and 5.5% respectively. PMC patients were older (54.4±13.3 vs 51.1±13.1 years), had lower Ki67 expression, lower incidence of nodal metastasis (N+) than MMC patients (p values <0.05). At median follow-up of 58 months, the 5-year overall survival rate of non-metastatic patients was 86.6%. Univariate analysis revealed that significant factors for poorer OS were MMC subtype (p=0.02), large tumor size (T) (p<0.001), N+ (p<0.001), HER2 overexpression (p<0.001), PR negative (p=0.02), and high Ki67 (p=0.02). Multivariate analysis showed nodal metastasis (N+) to be the most significant prognostic factor (HR=3.3; 95%CI 1.5-7.1), followed by high T stage (HR=2.9; 95%CI 1.4-6.3), HER2 overexpression (HR=2.5; 95%CI 1.2-5.3) and MMC subtype (HR=1.9; 95%CI 1.0-3.9). Amongst 245 patients with stage T1-2N0M0, 40.8% of those treated with CT related to worse overall survival (5-year OS 88.0% vs 95.6%, p=0.04).
Conclusions
The majority of MBC are luminal subtypes and associated with good prognosis. Poor prognostic factors of women with MBC are high T, N stage, HER2 overexpression and MMC subtype. Chemotherapy in stage T1-2N0M0 brings a worse survival outcome compared to endocrine therapy. Given the low response rate to neoadjuvant CT, upfront surgery is appropriate for MBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract